GlassScriptPhysician profile
Sean Jackson
NPI 1720685050
$11,238.53
in general payments reported to CMS, 2019-2025
23 companies · $782 in 2025
The $782 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $856 · 2022: $2,554 · 2023: $3,328 · 2024: $3,719 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,645 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,644.57 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,589.54 | 2021-2025 | |
| Amgen INC. | $1,439.31 | 2021-2025 | Enbrel, Otezla, Prolia |
| Ucb, INC. | $1,138.77 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,010.36 | 2022-2025 | |
| Janssen Biotech, INC. | $924.76 | 2022-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $507.73 | 2022-2025 | Acthar |
| Pfizer INC. | $428.45 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.29 | 2022-2025 | Orencia |
| Lilly USA, LLC | $390.67 | 2022-2025 | Taltz, Omvoh |
| Astrazeneca Pharmaceuticals LP | $316.80 | 2021-2024 | Saphnelo |
| Glaxosmithkline, LLC. | $297.30 | 2023-2025 | Benlysta |
| Organon LLC | $163.52 | 2024-2025 | Hadlima |
| Ani Pharmaceuticals, INC. | $124.18 | 2022-2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.11 | 2021-2023 | Cyltezo, Ofev |
| Fresenius Kabi USA, LLC | $103.01 | 2023-2024 | Idacio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $59.20 | 2022 | |
| Aurinia Pharma U.S., INC. | $57.98 | 2022-2024 | Lupkynis |
| Sandoz INC. | $46.28 | 2023 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $34.40 | 2022 | |
| Madrigal Pharmaceuticals | $33.58 | 2025 | Rezdiffra |
| Orphalan INC | $24.82 | 2025 | Cuvrior |
| Kyowa Kirin, INC. | $21.86 | 2024 | Crysvita |
| Radius Health, INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.